Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
April 28 2023 - 4:05PM
Business Wire
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced the appointment of Susan Molineaux, Ph.D., to its Board
of Directors, effective as of the date of the Company’s upcoming
annual meeting of shareholders in June 2023. Concurrent with Dr.
Molineaux’s appointment as of the date of the annual meeting, Jerel
Davis, Ph.D., Managing Director at Versant Ventures and a founding
member of Repare’s Board of Directors, will step down from the
Board.
“On behalf of the Company and our Board of Directors, I want to
thank Jerel for his service and partnership that have been
instrumental in building Repare into the leading precision oncology
that it is today,” said Lloyd M. Segal, President and Chief
Executive Officer of Repare. “He has made significant contributions
from the outset, and I also would like to personally thank Jerel
for his ongoing support. In parallel, we are honored to welcome Dr.
Molineaux to our Board. Her deep experience and accomplishments as
an oncology drug developer will provide valuable guidance as Repare
continues to advance and expand its clinical pipeline.”
“It has been my pleasure to work with the Repare management team
and serve on the Company's Board since its founding in 2016," said
Dr. Davis. "I look forward to Repare’s continued progress and have
the deepest conviction in the team’s ability to deliver synthetic
lethal therapies for patients with unmet need."
Dr. Molineaux currently serves as President and Chief Executive
Officer of Para Therapeutics Inc., a position she has held since
April 2023. Most recently, she served as President and Chief
Executive Officer of Calithera Biosciences, Inc., which she
co-founded in March 2010. Prior to Calithera, she was a co-founder
of Proteolix, Inc., and served as Chief Scientific Officer before
becoming President and Chief Executive Officer until the Company’s
acquisition by Onyx Pharmaceuticals, Inc. in November 2009.
Previously, she held various senior scientific and management
positions including at Rigel Pharmaceuticals, Inc. and Merck &
Co.
Dr. Molineaux currently serves as a member of the Boards of
Directors of Geron Corp., Cyteir Therapeutics, Inc. and Smith
College, and is a Scientific Advisor for Lightstone Ventures. Dr.
Molineaux earned a B.S. in Biology from Smith College and a Ph.D.
in Molecular Biology from Johns Hopkins University, and completed a
postdoctoral fellowship at Columbia University.
“I am thrilled to join the Board of Repare at such an exciting
time in the Company’s growth and evolution,” said Dr. Molineaux. “I
look forward to collaborating with my fellow Board members and
contributing to the executive team’s execution of its business
plans and strategy to deliver synthetic lethal medicines that
meaningfully improve the lives of cancer patients.”
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes RP-6306, a PKMYT1
inhibitor currently in Phase 1 clinical development; camonsertib
(also known as RP-3500 or RG6526), a potential leading ATR
inhibitor currently in Phase 1/2 clinical development and partnered
with Roche; a preclinical Polθ inhibitor program; as well as
several additional, undisclosed preclinical programs. For more
information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
and securities laws in Canada. All statements in this press release
other than statements of historical facts are “forward-looking
statements. These statements may be identified by words such as
“aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding: the planned
director transition and the Company’s ability to deliver synthetic
lethality medicines that meaningfully improve the lives of cancer
patients. These forward-looking statements are based on the
Company’s expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties that could cause the Company’s clinical
development programs, future results or performance to differ
materially from those expressed or implied by the forward-looking
statements. Many factors may cause differences between current
expectations and actual results, including: the impacts of
macroeconomic conditions, including the COVID-19 pandemic, the
conflict in Ukraine, rising inflation, and uncertain credit and
financial markets on the Company’s business, clinical trials and
financial position; unexpected safety or efficacy data observed
during preclinical studies or clinical trials; clinical trial site
activation or enrollment rates that are lower than expected;
changes in expected or existing competition; changes in the
regulatory environment; the uncertainties and timing of the
regulatory approval process; and unexpected litigation or other
disputes. Other factors that may cause the Company’s actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are identified in the section
titled "Risk Factors" in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022 filed with the Securities and
Exchange Commission (“SEC”) and the Québec Autorité des Marchés
Financiers ("AMF") on February 28, 2023, and its other documents
subsequently filed with or furnished to the SEC and AMF. The
Company expressly disclaims any obligation to update any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise, except as otherwise required by law. For more
information, please visit reparerx.com and follow Repare on Twitter
at @RepareRx and on LinkedIn at
https://www.linkedin.com/company/repare-therapeutics/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230428005433/en/
Repare Contact: Robin Garner Executive Director and Head
of Investor Relations Repare Therapeutics Inc. info@reparerx.com
Investors: Matthew DeYoung Argot Partners
repare@argotpartners.com Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Apr 2024 to May 2024
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From May 2023 to May 2024